Juge P.A. Lee J.S. Ebstein E. et al.

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

N Engl J Med. 379: 2209-2219Gabbay E. Tarala R. Will R. et al.

Interstitial lung disease in recent onset rheumatoid arthritis.

Am J Respir Crit Care Med. 156: 528-535Walker U.A. Tyndall A. Czirjak L. et al.

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.

Ann Rheum Dis. 66: 754-763Fathi M. Dastmalchi M. Rasmussen E. et al.

Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis.

Ann Rheum Dis. 63: 297-301Reiseter S. Gunnarsson R. Mogens Aalokken T. et al.

Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study.

Rheumatology (Oxford). 57: 255-262Flament T. Bigot A. Chaigne B. et al.

Pulmonary manifestations of Sjogren's syndrome.

Eur Respir Rev. 25: 110-123

Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

Arthritis Res Ther. 12: 213Flaherty K.R. Wells A.U. Cottin V. et al.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

The New Engl J Med. https://doi.org/10.1056/NEJMoa1908681Cottin V. Wollin L. Fischer A. et al.

Fibrosing interstitial lung diseases: knowns and unknowns.

Eur Respir Rev. 28https://doi.org/10.1183/16000617.0100-2018Adegunsoye A. Oldham J.M. Bellam S.K. et al.

Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.

Ann Am Thorac Soc. 16: 580-588Tashkin D.P. Elashoff R. Clements P.J. et al.

Cyclophosphamide versus placebo in scleroderma lung disease.

N Engl J Med. 354: 2655-2666Tashkin D.P. Roth M.D. Clements P.J. et al.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Lancet Respir Med. 4: 708-719Fischer A. Brown K.K. Du Bois R.M. et al.

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.

J Rheumatol. 40: 640-646Oldham J.M. Lee C. Valenzi E. et al.

Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.

Respir Med. 121: 117-122Huapaya J.A. Silhan L. Pinal-Fernandez I. et al.

Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Chest. 156: 896-906Sharma N. Putman M.S. Vij R. et al.

Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort.

J Rheumatol. 44: 1612-1618Witt L.J. Demchuk C. Curran J.J. et al.

Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease.

Pulm Pharmacol Ther. 36: 46-52Duarte A.C. Cordeiro A. Fernandes B.M. et al.

Rituximab in connective tissue disease-associated interstitial lung disease.

Clin Rheumatol. 38: 2001-2009Keir G.J. Maher T.M. Hansell D.M. et al.

Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.

Eur Respir J. 40: 641-648Koduri G. Norton S. Young A. et al.

Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort.

Rheumatology (Oxford). 49: 1483-1489

Changes in causes of death in systemic sclerosis, 1972-2002.

Ann Rheum Dis. 66: 940-944Khanna D. Lin C.J.F. Furst D.E. et al.

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet Respir Med. 8: 963-974Tashkin D.P. Elashoff R. Clements P.J. et al.

Cyclophosphamide versus placebo in scleroderma lung disease.

The New Engl J Med. 354: 2655-2666Tashkin D.P. Roth M.D. Clements P.J. et al.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Lancet Respir Med. 4: 708-719Pugashetti J.V. Kitich A. Alqalyoobi S. et al.

Derivation and Validation of a Diagnostic Prediction Tool for Interstitial Lung Disease.

Chest. https://doi.org/10.1016/j.chest.2020.02.044Bilgici A. Ulusoy H. Kuru O. et al.

Pulmonary involvement in rheumatoid arthritis.

Rheumatol Int. 25: 429-435Suliman Y.A. Dobrota R. Huscher D. et al.

Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.

Arthritis Rheumatol. 67: 3256-3261Wu A.C. Kiley J.P. Noel P.J. et al.

Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Am J Respir Crit Care Med. 198: e116-e136Reveille J.D. Solomon D.H.

American College of Rheumatology Ad Hoc Committee of Immunologic Testing G. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies.

Arthritis Rheum. 49: 399-412Nihtyanova S.I. Schreiber B.E. Ong V.H. et al.

Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis.

Arthritis Rheumatol. 66: 1625-1635Jandali B. Salazar G.A. Hudson M. et al.

The Effect of Anti-Scl -70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis.

ACR Open Rheumatol. 4: 345-351Walker U.A. Tyndall A. Czirjak L. et al.

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.

Ann Rheum Dis. 66: 754-763Liaskos C. Marou E. Simopoulou T. et al.

Disease-related autoantibody profile in patients with systemic sclerosis.

Autoimmunity. 50: 414-421Mitri G.M. Lucas M. Fertig N. et al.

A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.

Arthritis Rheum. 48: 203-209Lazzaroni M.-G. Marasco E. Campochiaro C. et al.

The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.

Rheumatology. 60: 5028-5041Hudson M. Pope J. Mahler M. et al.

Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis.

Arthritis Res Ther. 14: R50Mierau R. Moinzadeh P. Riemekasten G. et al.

Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features.

Arthritis Res Ther. 13: R172Wangkaew S. Euathrongchit J. Wattanawittawas P. et al.

Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study.

Mod Rheumatol. 26: 588-593

Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody.

BMJ Open. 11: e040465Kelly C.A. Saravanan V. Nisar M. et al.

Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.

Rheumatology (Oxford). 53: 1676-1682Doyle T.J. Patel A.S. Hatabu H. et al.

Detection of Rheumatoid Arthritis–Interstitial Lung Disease Is Enhanced by Serum Biomarkers.

Am J Respir Crit Care Med. 191: 1403-1412Giles J.T. Danoff S.K. Sokolove J. et al.

Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease.

Ann Rheum Dis. 73: 1487-1494Richards T.J. Eggebeen A. Gibson K. et al.

Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.

Arthritis Rheum. 60: 2183-2192Marie I. Josse S. Decaux O. et al.

Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.

Autoimmun Rev. 11: 739-745Sato S. Hirakata M. Kuwana M. et al.

Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis.

Arthritis Rheum. 52: 1571-1576Tsuji H. Nakashima R. Hosono Y. et al.

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Pos.

Arthritis Rheumatol. 72: 488-498Hamaguchi Y. Kuwana M. Hoshino K. et al.

Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis.

Arch Dermatol. 147: 391Koga T. Fujikawa K. Horai Y. et al.

The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.

Rheumatology (Oxford). 51: 1278-1284Fiorentino D. Chung L. Zwerner J. et al.

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study.

J Am Acad Dermatol. 65: 25-34Hall J.C. Casciola-Rosen L. Samedy L.-A. et al.

Anti-Melanoma Differentiation-Associated Protein 5-Associated Dermatomyositis: Expanding the Clinical Spectrum.

Arthritis Care Res. 65: 1307-1315Ishikawa N. Hattori N. Yokoyama A. et al.

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.

Respir Investig. 50: 3-13Asano Y. Ihn H. Yamane K. et al.

Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.

Arthritis Rheum. 44: 1363-1369Hant F.N. Ludwicka-Bradley A. Wang H.-J. et al.

Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma.

The J Rheumatol. 36: 773-780Hasegawa M. Fujimoto M. Hamaguchi Y. et al.

Use of Serum Clara Cell 16-kDa (CC16) Levels as a Potential Indicator of Active Pulmonary Fibrosis in Systemic Sclerosis.

The J Rheumatol. 38: 877-884Fotoh D.S. Helal A. Rizk M.S. et al.

Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis–associated interstitial lung disease.

Clin Rheumatol. 40: 2689-2697Zheng M. Lou A. Zhang H. et al.

Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population.

Rheumatol Ther. 8: 517-527Qin Y. Wang Y. Meng F. et al.

Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease.

Arthritis Res Ther. 24https://doi.org/10.1186/s13075-022-02800-2Takanashi S. Nishina N. Nakazawa M. et al.

Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.

Rheumatology. 58: 1034-1039Lee J.S. Lee E.Y. Ha Y.-J. et al.

Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.

Arthritis Res Ther. 21https://doi.org/10.1186/s13075-019-1835-9Fathi M. Barbasso Helmers S. Lundberg I.E.

KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.

J Intern Med. 271: 589-597Hasegawa M. Fujimoto M. Matsushita T. et al.

Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Clin Rheumatol. 30: 231-237Chen F. Lu X. Shu X. et al.

Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.

Intern Med J. 45: 641-647Takahashi H. Kuroki Y. Tanaka H. et al.

Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis.

Am J Respir Crit Care Med. 162: 258-263

Cytokine expression in patients with interstitial lung disease in primary Sjogren's syndrome and its clinical significance.

Am J Transl Res. 13: 8391-8396Yu M. Guo Y. Zhang P. et al.

Increased circulating Wnt5a protein in patients with rheumatoid arthritis-associated interstitial pneumonia (RA-ILD).

Immunobiology. 224: 551-559Maher T.M. Nambiar A.M. Wells A.U.

The role of precision medicine in interstitial lung disease.

Eur Respir J. 60: 2102146Kass D.J. Nouraie M. Glassberg M.K. et al.

Comparative Profiling of Serum Protein Biomarkers in Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.

Arthritis Rheumatol. 72: 409-419Raghu G. Remy-Jardin M. Richeldi L. et al.

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Am J Respir Crit Care Med. 205: e18-e47Guillen-Del Castillo A. Pilar Simeon-Aznar C. Fonollosa-Pla V. et al.

Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody.

Semin Arthritis Rheum. 44: 331-337

Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.

Rheumatology (Oxford). 60: 3343-3351Bauhammer J. Blank N. Max R. et al.

Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.

J Rheumatol. 43: 1566-1574Arai S. Kurasawa K. Maezawa R. et al.

Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis.

Mod Rheumatol. 23: 872-883Kamiya Y. Fujisawa T. Kono M. et al.

Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases.

Respir Med. 159: 105811Satoh H. Kurishima K. Ishikawa H. et al.

Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.

J Intern Med. 260: 429-434Salazar G.A. Kuwana M. Wu M. et al.

KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.

The J Rheumatol. 45: 1153-1158Gono T. Masui K. Nishina N. et al.

Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis–Associated Interstitial Lung Disease.

Arthritis Rheumatol. 73: 677-686Bowman W.S. Newton C.A. Linderholm A.L. et al.

Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis.

Lancet Respir Med. https://doi.org/10.1016/S2213-2600(21)00503-8Noble P.W. Albera C. Bradford W.Z. et al.

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Comparative Study Multicenter Study Randomized Controlled Trial Research Support.

Non-U.S Gov't Lancet. 377: 1760-1769Richeldi L. Du Bois R.M. Raghu G. et al.

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.

New Engl J Med. 370: 2071-2082

CT evaluation of diffuse infiltrative lung disease: dose considerations and optimal technique.

J Thorac Imaging. 24: 252-259

High-resolution CT of the lungs.

AJR Am J Roentgenol. 177: 501-519Ghodrati S. Pugashetti J.V. Kadoch M.A. et al.

Diagnostic Accuracy of Chest Radiography for Detecting Fibrotic Interstitial Lung Disease.

Ann Am Thorac Soc. https://doi.org/10.1513/AnnalsATS.202112-1377RLSchurawitzki H. Stiglbauer R. Graninger W. et al.

Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography.

Radiology. 176: 755-759https://doi.org/10.1148/radiology.176.3.2389033Hoffmann-Vold A.-M. Maher T.M. Philpot E.E. et al.

The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements.

Lancet Rheumatol. 2: e71-e83https://doi.org/10.1016/s2665-9913(19)30144-4Bruni C. Chung L. Hoffmann-Vold A.M. et al.

High-resolution computed tomography of the chest for the screening, re-screening and follow-up of systemic sclerosis-associated interstitial lung disease: a EUSTAR-SCTC survey.

Clin Exp Rheumatol. https://doi.org/10.55563/clinexprheumatol/7ry6zzPritchard D. Adegunsoye A. Lafond E. et al.

Diagnostic test interpretation and referral delay in patients with interstitial lung disease.

Respir Res. 20: 253https://doi.org/10.1186/s12931-019-1228-2Cano-Jiménez E. Vázquez Rodríguez T. Martín-Robles I. et al.

Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis.

Scientific Rep. 11https://doi.org/10.1038/s41598-021-88734-2Kim E.J. Elicker B.M. Maldonado F. et al.

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.

Eur Respir J. 35: 1322-1328Nurmi H.M. Kettunen H.-P. Suoranta S.-K. et al.

Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease.

Respir Med. 134: 24-30Yamakawa H. Sato S. Tsumiyama E. et al.

Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria.

J Thorac Dis. 11: 5247-5257Winstone T.A. Assayag D. Wilcox P.G. et al.

Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review.

Chest. 146: 422-436Hoffmann-Vold A.-M. Aaløkken T.M. Lund M.B. et al.

Predictive Value of Serial High-Resolution Computed Tomography Analyses and Concurrent Lung Function Tests in Systemic Sclerosis.

Arthritis Rheumatol. 67: 2205-2212Kocheril S.V. Appleton B.E. Somers E.C. et al.

Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia.

Arthritis Rheum. 53: 549-557Walsh S.L.F. Sverzellati N. Devaraj A. et al.

Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants.

Thorax. 69: 216-222Khanna D. Tseng C.-H. Farmani N. et al.

Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group.

Arthritis Rheum. 63: 3078-3085Moore O.A. Goh N. Corte T. et al.

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

Rheumatology. 52: 155-160Goh N.S. Desai S.R. Veeraraghavan S. et al.

Interstitial lung disease in systemic sclerosis: a simple staging system.

Am J Respir Crit Care Med. 177: 1248-1254Raghu G. Remy-Jardin M. Myers J.L. et al.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Am J Respir Crit Care Med. 198: e44-e68Desai S.R. Veeraraghavan S. Hansell D.M. et al.

CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.

Radiology. 232: 560-567Travis W.D. Costabel U. Hansell D.M. et al.

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Am J Respir Crit Care Med. 188: 733-748Bendstrup E. Moller J. Kronborg-White S. et al.

Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians.

J Clin Med. 8https://doi.org/10.3390/jcm8122038Tanaka N. Kim J.S. Newell J.D. et al.

Rheumatoid arthritis-related lung diseases: CT findings.

Radiology. 232: 81-91Assayag D. Lubin M. Lee J.S. et al.

Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.

Respirology. 19: 493-500Liu H. Xie S. Liang T. et al.

Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome.

Eur Radiol. 29: 5349-5357Maillet T. Goletto T. Beltramo G. et al.

Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor.

J Autoimmun. 106: 102338https://doi.org/10.1016/j.jaut.2019.102338Kim H.C. Lee J.S. Lee E.Y. et al.

Risk prediction model in rheumatoid arthritis-associated interstitial lung disease.

Respirology. 25: 1257-1264Solomon J.J. Chung J.H. Cosgrove G.P. et al.

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.

Eur Respir J. 47: 588-596Pugashetti J.V. Adegunsoye A. Wu Z. et al.

Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.

Am J Respir Crit Care Med. 207: 69-76Oldham J.M. Lee C.T. Wu Z. et al.

Lung function trajectory in progressive fibrosing interstitial lung disease.

Eur Respir J. https://doi.org/10.1183/13993003.01396-2021Watadani T. Sakai F. Johkoh T. et al.

Interobserver variability in the CT assessment of honeycombing in the lungs.

Radiology. 266: 936-944Nathan S.D. Pastre J. Ksovreli I. et al.

HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines.

Ther Adv Respir Dis. 14 ()Anthimopoulos M. Christodoulidis S. Ebner L. et al.

Lung Pattern Classification for Interstitial Lung Diseases Using a Deep Convolutional Neural Network.

IEEE Trans Med Imaging. 35: 1207-1216Kim G.B. Jung K.-H. Lee Y. et al.

Comparison of Shallow and Deep Learning Methods on Classifying the Regional Pattern of Diffuse Lung Disease.

J Digital Imaging. 31: 415-424Walsh S.L.F. Calandriello L. Silva M. et al.

Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study.

Lancet Respir Med. 6: 837-845Ash S.Y. Harmouche R. Vallejo D.L.L. et al.

Densitometric and local histogram based analysis of computed tomography images in patients with idiopathic pulmonary fibrosis.

Respir Res. 18https://doi.org/10.1186/s12931-017-0527-8Best A.C. Meng J. Lynch A.M. et al.

Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality.

Radiology. 246: 935-940